Literature DB >> 18597213

Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.

J E Foley1, M Ligueros-Saylan, Y-L He, J J Holst, C F Deacon, B E Dunning, A Leone-Jones, T Yu, D E Kelley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18597213     DOI： 10.1055/s-2008-1078754

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN： 0018-5043            Impact factor:   2.936


× No keyword cloud information.
  14 in total

Review 1.  Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.

Authors:  Bo Ahrén; James E Foley
Journal:  Diabetologia       Date:  2016-02-19       Impact factor: 10.122

Review 2.  Clinical pharmacokinetics and pharmacodynamics of vildagliptin.

Authors:  Yan-Ling He
Journal:  Clin Pharmacokinet       Date:  2012-03-01       Impact factor: 6.447

3.  The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes.

Authors:  Siri Fredheim; Marie-Louise M Andersen; Sven Pörksen; Lotte B Nielsen; Christian Pipper; Lars Hansen; Jens J Holst; Jane Thomsen; Jesper Johannesen; Henrik B Mortensen; Jannet Svensson
Journal:  Diabetologia       Date:  2014-12-27       Impact factor: 10.122

Review 4.  Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.

Authors:  Anja Schweizer; James E Foley; Wolfgang Kothny; Bo Ahrén
Journal:  Vasc Health Risk Manag       Date:  2013-02-15

5.  Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.

Authors:  Ottavio Giampietro; Chiara Giampietro; Luca Della Bartola; Maria Chiara Masoni; Elena Matteucci
Journal:  Drug Des Devel Ther       Date:  2013-02-14       Impact factor: 4.162

6.  Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes.

Authors:  Miyako Kishimoto; Mitsuhiko Noda
Journal:  Diabetes Ther       Date:  2012-09-28       Impact factor: 2.945

7.  Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management.

Authors:  Sylvie Dejager; Anja Schweizer
Journal:  Diabetes Ther       Date:  2011-02-08       Impact factor: 2.945

8.  Emerging role of insulin with incretin therapies for management of type 2 diabetes.

Authors:  Rupa Ahluwalia; Jiten Vora
Journal:  Diabetes Ther       Date:  2011-07-21       Impact factor: 2.945

9.  Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.

Authors:  Bo Ahrén; James E Foley; Ele Ferrannini; David R Matthews; Bernard Zinman; Sylvie Dejager; Vivian A Fonseca
Journal:  Diabetes Care       Date:  2010-01-12       Impact factor: 17.152

10.  Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes.

Authors:  Miyako Kishimoto
Journal:  Diabetes Metab Syndr Obes       Date:  2013-05-06       Impact factor: 3.168
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.